Nebenwirkungen · Blincyto
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion. · Abschnitt 4.8 · PDF-Seite 20
HOS-130879 · Präparat HOS-096973
In the randomised phase III clinical study (N = 267) and the single-arm phase II clinical study (N = 189) in patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL treated with BLINCYTO, 22.4% of patients reported elevated liver enzymes and associated signs/symptoms. Serious and grade ≥ 3 adverse reactions (such as ALT increased, AST increased, and blood bilirubin increased) were observed in 1.5% and 13.6% of patients respectively. The median time to onset to the first event was 4 days from the start of BLINCYTO treatment initiation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:23:00Z · SHA-256 668031da99230a14f14436294725ac020f67d97c55a5ae00fb7031434493482b · Passage 4931e8bcb99b0fc986b51831bf078a630d0f136d822177f0f19721cf0289c614 · Zeichen 14401–14976 im Abschnitt